|Articles|May 16, 2019

Road Ahead Still Difficult for Biosimilar Producers in US

The FDA has finalized its guidance on interchangeable biosimilars, but the new specifications will still make it a difficult for biosimilar producers looking to make headway in the United States. GlobalData’s Senior Immunology Pharma Analyst, Rose Joachim, weighs in.

See what she has to say here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related Articles

Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
Phase IV Trial Shows Strong Immune Response from Moderna’s Updated Spikevax Against LP.8.1 Variant of COVID-19
September 17th 2025
Generative AI Transforms Clinical Study Report Development
September 16th 2025
Why Clinical Trials Are at a Crossroads and How Site Networks Are the Key to Success
September 16th 2025

Trending on Applied Clinical Trials Online

Why Clinical Trials Are at a Crossroads and How Site Networks Are the Key to Success

IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes

Generative AI Transforms Clinical Study Report Development

Everything to Know About FDA’s Push Towards Radical Transparency in 2025

Managing Background Therapies in the NIMBLE Phase III Trial

© 2025 MJH Life Sciences^®

All rights reserved.